Pyridine nucleotide levels in liver of rats fed clofibrate- or pyrazinamide-containing diets.
Hepatic NAD+, NADH, and NADPH were increased significantly 3 days after feeding rats with a 0.25% clofibrate diet, increased further after 8 days, and stayed at the same levels 14 days after feeding the diet. The NAD+/NADH ratio was decreased significantly by feeding the clofibrate diet for 8 days, while the ratio remained unchanged with a 1% pyrazinamide diet. Hepatic quinolinate phosphoribosyltransferase (QAPRTase) (EC 2.4.2.19) activity was increased to 1.8 and 1.3 times that of the control animals in the clofibrate- and the pyrazinamide-fed rats, respectively, while hepatic aminocarboxymuconate-semialdehyde decarboxylase (ACMSDase) (EC 4.1.1.45) activity was decreased to 0 and 19% of that of the control animals. The heat-treated liver homogenate from the pyrazinamide-fed rats contained inhibitory activity toward ACMSDase, while no inhibitory activity was found in the liver homogenate of the clofibrate-fed animals. We conclude that these changes of enzyme activities, which seem due to different mechanisms, may contribute to the increase of pyridine nucleotides in the liver of rats fed clofibrate or pyrazinamide.
Shin
M
M
School of Pharmacy, Kobe Gakuin University, Japan. shin@pharm.kobegakuin.ac.jp
Iwamoto
N
N
Yamashita
M
M
Sano
K
K
Umezawa
C
C
D000818:Animals; D002994:Clofibrate / Q000008:administration & dosage*; D004032:Diet; D005260:Female; D000960:Hypolipidemic Agents / Q000008:administration & dosage*; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D009243:NAD / Q000378:metabolism*; D009249:NADP / Q000378:metabolism*; D011718:Pyrazinamide / Q000008:administration & dosage*; D051381:Rats; D017207:Rats, Sprague-Dawley
D000960:Hypolipidemic Agents; D009243:NAD; D011718:Pyrazinamide; D009249:NADP; D002994:Clofibrate